§ Claim under review · Mixed
"A study published in the peer-reviewed journal Veterinary Medicine and Science (DOI: 10.1002/vms3.118) found that one dose of a broccoli sprout supplement reduced cancer-related enzyme activity by 24% in dogs within 24 hours." Post image text: "A teaspoon of broccoli sprouts gives your dog a powerful sulforaphane boost. One dose reduced cancer-related enzyme activity by 24% in 24 hours, supporting the body's natural defenses."
Verdict
Partially accurate but misleading
Confidence
HighSummary
The study behind this ad is real. Researchers at Oregon State University gave one dose of a concentrated broccoli sprout supplement to 10 healthy dogs and measured a 24.4% drop in the activity of an enzyme called histone deacetylase in blood cells 24 hours later. That part checks out. What the ad leaves out matters. Histone deacetylase is a normal enzyme found in healthy cells, not a cancer enzyme, and it was measured in blood, not in tumors. No dog in the study had cancer, there was no control or placebo group, and the study measured only absorption and an enzyme marker, not any health outcome. The supplement used was a capsule product with active myrosinase, not a teaspoon of the sprouts being sold, and the multi-ingredient product being advertised was not tested at all. The finding is a reasonable early signal that sulforaphane is absorbed and active in dogs, but it does not show that adding sprouts to a dog's bowl protects against cancer.
The readings
key figures from the evidencedecrease in HDAC activity at 24 hours versus baseline in dogs
healthy adult dogs in the study
HDAC decrease in women after sulforaphane, cited for comparison
Why this verdict
Evidence
The cited DOI resolves to a real, correctly described paper. The stated objective was to provide a detailed analysis of sulforaphane absorption following a single oral dose of a broccoli sprout supplement in normal dogs, and a single dose of broccoli sprout supplement with active myrosinase was orally administered to 10 healthy adult dogs, with blood and urine collected before dosing and at various time points after.
HDAC activity was determined in peripheral blood mononuclear cells at 0 h (baseline), 1, 2 and 24 h post-consumption, with data expressed as percentage change in HDAC activity compared to baseline.
A trend toward decreased HDAC activity was observed at 1 h and a significant decrease was observed at 24 h post-consumption, a 24.4% decrease versus baseline, with one dog excluded from the analysis due to haemolysis in the PBMC sample. The authors themselves benchmarked this against human data: the study population had a decrease in HDAC activity by 24.4% from baseline, compared with an 18% decrease in women scheduled for breast biopsy following sulforaphane supplementation.
The enzyme in question is histone deacetylase, an epigenetic regulatory enzyme present in normal cells, not a cancer-specific marker. The paper's framing is mechanistic: sulforaphane is a naturally occurring isothiocyanate derived from glucoraphanin found in cruciferous vegetables, and has been shown to suppress tumour growth by several mechanisms including inhibiting histone deacetylases.
Findings
✓ What's accurate 5
- The journal, DOI, and peer-reviewed status are cited correctly. The paper exists and is indexed in PubMed.
- The study was genuinely conducted in dogs, not only in rodents or cell culture.
- A single dose was used, and the measured decrease in HDAC activity at 24 hours was 24.4%, which rounds to the claimed 24%.
- The decrease at 24 hours was reported as statistically significant.
- Sulforaphane is a known HDAC inhibitor and Nrf2 activator, and the study confirmed oral absorption of sulforaphane in dogs.
≈ What's misleading 6
- Omitted qualifier / mislabeling: "cancer-related enzyme" describes histone deacetylase, a normal regulatory enzyme found in healthy cells throughout the body. It was measured in circulating white blood cells of healthy dogs, not in tumor tissue. Calling it a "cancer-related enzyme" invites readers to think a cancer process was measured and reduced. It was not.
- Marketing substitution of product: the study used concentrated broccoli sprout supplement capsules with active myrosinase, swallowed whole. The post attaches the finding to "a teaspoon of broccoli sprouts" and to a branded packaged sprout product and a multi-ingredient supplement called Liver Lift. Neither the retail sprouts nor Liver Lift was tested in this study, and no dose equivalence between a teaspoon of sprouts and the studied capsule dose is established in the post.
- Exaggeration of evidence strength: the design was a small single-arm bioavailability study with 10 healthy dogs and no control or placebo group. A biomarker shift measured once, against each animal's own baseline, in nine analyzable dogs, is preliminary pharmacodynamic data.
- Unsupported outcome inference: "supporting the body's natural defenses" and "defenses against cancer-related changes" imply a protective health outcome. The study measured absorption and an enzyme activity marker. It did not measure cancer incidence, tumor growth, immune function, or any clinical outcome.
- Temporal overreach: a single-timepoint change 24 hours after one dose is presented in a context promoting ongoing daily supplementation. The paper itself notes sulforaphane levels fall to low concentrations by 24 hours, and the study says nothing about sustained or repeated dosing effects.
- Undisclosed commercial framing: the claim appears inside an advertisement with a call to action to receive product details. That does not make the number wrong, but the scientific finding is being used to sell a product it did not test.
? What's uncertain 5
- The exact supplement brand, capsule count, and milligram dose per dog used in the Curran study were not retrieved verbatim in my searches. The related trial from the same research group indicates a BroccoMax based regimen derived from this bioavailability work, but I could not confirm the precise single-dose amount in the 2018 paper itself.
- Whether a teaspoon of the specific commercial sprouts shown would deliver a comparable glucoraphanin and active myrosinase dose is unverified. No source was found making that equivalence.
- Confidence intervals and the exact p value for the 24.4% change were not retrieved beyond the stated significance threshold of P < 0.05.
- The caption's separate claim that young sprouts contain dramatically more sulforaphane precursor than mature broccoli was not independently verified in this investigation. Background from training data, clearly labeled as such and not a retrieved source: published work has reported substantially higher glucoraphanin content in young broccoli sprouts than in mature heads, so this element is plausible but was not confirmed here.
- Secondary uninvestigated claim: the composition and effects of the Liver Lift product itself were not examined.
Sources
4 of 4 linked to recordsCurran KM, Bracha S, Wong CP, Beaver LM, Stevens JF, Ho E. "Sulforaphane absorption and histone deacetylase activity following single dosing of broccoli sprout supplement in normal dogs." Vet Med Sci. 2018 Nov;4(4):357-363
PubMed record for the same study
Skorupski/Bracha group follow-up: "Prospective evaluation of the lymph node proteome in dogs with multicentric lymphoma supplemented with sulforaphane," J Vet Intern Med 2020;34(5):2036
National Canine Cancer Foundation explainer citing the Curran study